Akiram Therapeutics

Akiram Therapeutics
About Us
Contacts
Quotes
Change country

Follow us:
Share:
Subscribe:

About Us

Akiram Therapeutics is a Swedish biotech company focused on the development of targeted radioimmunotherapy for cancer, which is based on a proprietary antibody targeting the cancer marker CD44v6 combined with a radiation component. The therapy has generated strong preclinical results in cancer models in conditions that currently lack effective treatments. With the potential for its drug candidate to be classified as an orphan drug and recognized as first-in-class, the company is dedicated to advancing research in this field, including indications in head and neck cancer, lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, Akiram Therapeutics is staffed with experts in radiation science research, cancer precision medicine, and drug development. To learn more, please visit Akiram’s website and follow Akiram on LinkedIn.

Contacts

Marika Nestor

CEO

+46702341881
https://akiramtherapeutics.se/
marika.nestor@akiramtherapeutics.com

Quotes

The start of the Phase 1 clinical trial is a significant milestone for Akiram and an important step forward in molecular radiation therapy. We are excited to collaborate with Karolinska University Hospital and are confident in AKIR001's potential to improve treatment outcomes for patients.

Marika Nestor, CEO, Akiram Therapeutics

177Lu-AKIR001 has the potential to transform how we treat hard-to-treat tumors and could represent a major advancement in precision medicine.

Renske Altena, Senior Physician and Primary Investigator in oncology and internal medicine at Karolinska Comprehensive Cancer Center

177Lu-AKIR001 has shown great preclinical potential to transform the treatment of CD44v6-expressing tumors. We are looking forward to starting phase 1 studies later this fall, with the goal of offering new, targeted treatment options for patients with hard-to-treat cancers. The selection of our presentation as one of the top-rated talks is a clear recognition of the promising research, and we are excited to share the results with the international scientific community.

Marika Nestor, CEO, Akiram Therapeutics

With this agreement and the GMP production of the affinity carrier in place, we have everything needed to apply for a first-in-human clinical study in 2024. We are very excited and strongly motivated to progress this important project in close collaboration with our clinical colleagues at Karolinska University Hospital.

Marika Nestor, CEO, Akiram Therapeutics

It is with great pleasure that we welcome Anna Törner and Peder Walberg to Akiram's board. We are facing important developmental steps, and their investment and commitment to the company are strong indications of confidence in our strategic direction and our ability to realize our goals in cancer treatment.

Marika Nestor, CEO, Akiram Therapeutics

The grant is a testament to our commitment to pioneering cancer treatments. This generous support from the Erling-Persson Foundation allows us to advance our mission, offering hope and potential solutions to individuals suffering from incurable cancers.

Marika Nestor, CEO, Akiram Therapeutics

We are honored to have the opportunity to present at the Annual EANM Congress. We look forward to sharing promising data about our drug candidate, which we believe holds the potential to significantly impact patient care and radiopharmaceutical sciences in the future. Participating in this global conversation that's shaping the future of Nuclear Medicine is genuinely exciting.

Dr. Anja Mortenson, co-founder and CTO, Akiram Therapeutics

We would like to thank Sciety and all those who have participated in this successful issue for the great confidence in Akiram and our drug candidate. We now have the means to continue our work at full speed and take the next important steps on our exciting journey. We are very eager to continue the development of our drug candidate and to initiate phase I clinical studies.

Marika Nestor, CEO, Akiram Therapeutics

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory